Loading investment round...
Discover
Tools
Account
Loading investment round...
Degron Therapeutics — Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Degron Therapeutics has closed a $40 million Series A Extension, a follow-on round led by LAPAM CAPITAL. This funding will accelerate the development of its molecular glue degrader (MGD) medicines, with a focus on advancing its pipeline through clinical trials. The company aims to target previously undruggable or insufficiently drugged proteins with its novel therapeutic approach.
